Kyverna Therapeutics (KYTX) Live Share Price, Invest From India

Kyverna Therapeutics Stock Performance

as on March 4, 2026 at 6:08 am IST

Day's Low
Day's High
$7.91
Day's Price Range
$8.40
$8.11
2.47%
Downside
3.58%
Upside
52 Week's Low
52 Week's High
$1.78
52-Week Price Range
$13.67
$8.11
78.05%
Downside
68.56%
Upside

Kyverna Therapeutics share price movements today

Previous Close: $8.51
Open: $8.28
Volume: 484.6K
Day's Low - High: $7.91 - $8.40
52 Week Low - High: $1.78 - $13.67

Kyverna Therapeutics Historical Returns

1 Month Return: + 2.16 %
3 Month Return: + 18.52 %
1 Year Return: + 228.57 %
3 Year Return: 0 %
5 Year Return: 0 %

Kyverna Therapeutics Stock Fundamentals & Key Indicators

Check Kyverna Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$489.4M

EPS (TTM)

-3.6955

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-170.5M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-70.82%

Kyverna Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kyverna Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Kyverna Therapeutics	BUY	$489.4M	NA	NA	0.00%
Vertex Pharmaceuticals Incorporated	BUY	$126.2B	133.18%	32.47	32.94%
Alnylam Pharmaceuticals, Inc.	BUY	$44.2B	125.24%	142.88	8.45%
Beone Medicines Ltd	NA	$35.1B	NA	621.55	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$82.6B	77.02%	18.83	31.41%

Stock Returns calculator for Kyverna Therapeutics Stock including INR - Dollar returns

The Kyverna Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Kyverna Therapeutics investment value today

Current value as on today

₹3,18,632

Returns

₹2,18,632

(+218.63%)

Returns from Kyverna Therapeutics Stock

₹2,13,127 (+213.13%)

Dollar Returns*

₹5,505 (+5.5%)

Analyst Recommendation on Kyverna Therapeutics Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Kyverna Therapeutics. Average target price of $29.6

Kyverna Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Kyverna Therapeutics.

What analysts predicted

72.6%UPSIDE

Target Price

$29.6

Current Price

$8.11

Analyzed by

10 Analysts

Target

$29.60

Kyverna Therapeutics target price $29.6, a slight upside of 72.6% compared to current price of $8.11. According to 10 analysts rating.

Kyverna Therapeutics Stock’s Investor Sentiment and Interest

Search interest for Kyverna Therapeutics Stock has increased by 185% in the last 30 days, reflecting an upward trend in search activity.

Time period: February 2, 2026 to March 4, 2026

Change:185% versus previous 30 day period

Kyverna Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	-	-	-	-	2	-	-	-
Gross Profit	0	0	-17	0	0	-29	0	0	0	0
Operating Income	-13	-16	-21	0	-33	-38	-41	-47	-44	-38
EBITDA	-12	-14	-21	0	-28	-36	-36	-44	-41	-36
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-13	-15	-20	0	-28	-34	-37	-44	-42	-36
Income Tax Expense	-	-	0	0	-	-	-	-	-	-
Net Income	-13	-15	-20	0	-28	-34	-37	-44	-42	-36
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1852.22%	0.00%	0.00%	0.00%

Kyverna Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	5	7	-	-
Gross Profit	5	7	-1	-2
Operating Income	-26	-29	-62	-142
EBITDA	-25	-27	-58	-125
Interest Expense	0	0	0	0
Depreciation	0	1	1	2
Income Before Tax	-26	-28	-60	-127
Income Tax Expense	0	0	0	-127
Net Income	-26	-28	-60	-127
Net Profit Margin	-465.88%	-411.29%	0.00%	0.00%

Kyverna Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-15	-20	-26	-28	-34	-37	-44	-42	-36
Operating Cash Flow	-11	-18	-25	-24	-27	-37	-44	-31	-43
Investing Cash Flow	-54	31	-122	-67	0	29	5	29	22
Financing Cash Flow	34	-1	338	0	0	0	0	0	1
Change in Cash	-30	11	189	-92	-26	-8	-39	-3	-19

Kyverna Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024
Net Income	-28	-60	-127
Operating Cash Flow	-36	-52	-114
Investing Cash Flow	-14	-8	-160
Financing Cash Flow	11	58	337
Change in Cash	-38	-3	61

Insights on Kyverna Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 6 months, KYTX stock has moved up by 128.8%
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, KYTX has outperformed top 5 stocks with highest market-cap in its industry

About Kyverna Therapeutics

Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Organisation	Kyverna Therapeutics
Headquarters	5980 Horton Street, Emeryville, CA, United States, 94608
CEO	Mr. Warner Biddle
E-voting on shares	Click here to vote

Key Management of Kyverna Therapeutics

Name	Title
Mr. Warner Biddle	CEO & Director
Ms. Cara Bauer Ph.D.	Chief Human Resources Officer
Ms. Tracy Rossin	Senior Vice President of Corporate Affairs & Communications and Investor Relations
Dr. Naji H. Gehchan M.B.A., M.D.	Chief Medical & Development Officer
Ms. Christi L. Shaw	Executive Chairperson
Dr. Marc Grasso M.D.	Chief Financial Officer
Dr. Tom Van Blarcom Ph.D.	Senior VP & Head of Research
Mr. Mayo Pujols	Chief Technology Officer
Ms. Jessica Serra	Head of Investor Relations
Mr. Dan Maziasz	Chief Business Officer

FAQs

What is Kyverna Therapeutics share price today?

Kyverna Therapeutics share price today is $8.11 as on March 4, 2026 at 12:38 am IST. Kyverna Therapeutics share today touched a day high of $8.4 and a low of $7.91.

What is the 52 week high and 52 week low for Kyverna Therapeutics share?

Kyverna Therapeutics share touched a 52 week high of $13.67 on December 15, 2025 and a 52 week low of $1.78 on April 17, 2025. Kyverna Therapeutics stock price today i.e. March 4, 2026 at 12:38 am IST is trending at $8.11,which is 40.67% down from its 52 week high and 355.62% up from its 52 week low.

What is Kyverna Therapeutics's market capitalisation today?

Kyverna Therapeutics market capitalisation is $0.00T as on March 4, 2026 at 12:38 am IST.

How to invest in Kyverna Therapeutics Stock (KYTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Kyverna Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kyverna Therapeutics Shares that will get you 0.1850 shares as per Kyverna Therapeutics share price of $8.11 per share as on March 4, 2026 at 12:38 am IST.

What is the minimum amount required to buy Kyverna Therapeutics Stock (KYTX) from India?

Indian investors can start investing in Kyverna Therapeutics (KYTX) shares with as little as ₹92.074 or $1 (as of March 4, 2026 at 12:38 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹920.74 in Kyverna Therapeutics stock (as per the Rupee-Dollar exchange rate as on March 4, 2026 at 12:38 am IST). Based on Kyverna Therapeutics share’s latest price of $8.11 as on March 4, 2026 at 12:38 am IST, you will get 1.2330 shares of Kyverna Therapeutics. Learn more about fractional shares .